Please assess the completion status of the following clinical trial:

Trial Title: Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adult subjects (18-64 years) with a diagnosis of primary insomnia.~Exclusion Criteria:~* History of any sleep disorder, or any Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) axis I disorder other than primary insomnia.~* Sleep apnea, or restless legs syndrome.~* Daytime napping of more than 1 hour per day.~* Important caffeine consumption, heavy tobacco use, alcohol or drug abuse within 2 years prior to the screening visit.~* Unwillingness to refrain from drugs, over-the-counter or herbal medication having an effect on sleep or behavior.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): almorexant 200 mg
- 2 (Type: EXPERIMENTAL): almorexant 100 mg
- 3 (Type: PLACEBO_COMPARATOR): Placebo
- 4 (Type: ACTIVE_COMPARATOR): zolpidem 10 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).